Cannabis Clinical Trial
Official title:
Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial
Verified date | July 2019 |
Source | Karolinska Institutet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this randomized controlled trial is to investigate the effects of a Swedish
Internet-based treatment program for individuals from the general population with a regular
cannabis use.
The primary hypothesis to be tested is that the use of the Internet-based treatment program
will be associated with more cannabis-free days in comparison to only access to information
about cannabis use and its harmful effects.
The secondary hypotheses to be tested are:
1. That the use of the Internet-based treatment program will be associated with a larger
decline in cannabis consumption (frequency and quantity) among individuals with regular
cannabis use in comparison to only access to information about Cannabis use and its
harmful effects.
2. That the use of the Internet-based treatment program will be associated with a larger
decline in alcohol consumption, depression and anxiety and increased sense of coherence
in comparison to only access to information about Cannabis use and its harmful effects.
3. That the proportion of individuals who seek professional help or talk to their relatives
or friends about reducing or stopping cannabis use will be greater among those who use
the Internet-based treatment program than among those who only have access to
information about cannabis use and its harmful effects.
Recruitment procedure and baseline measures Study participants will be recruited through an
advertisement on Cannabishjalpen.se. Interested individuals will answer questions about
gender, age, country of birth, educational attainment, employment, marital status, living
situation, and cannabis use.
The intervention group Individuals randomized to the intervention group will directly after
randomization answer questions about alcohol use, use of drugs other than alcohol and
cannabis, depression, anxiety, a sense of context and whether they during the last 12 months
has received professional help to reduce or quit their cannabis use or during the same period
have raised this issue with their relatives or friends.
Further, they will fill out a survey on Internet-based services for individuals who wish to
reduce or quit their cannabis use. The study participants will then be informed that they,
within two days, will gain access to an internet based treatment program designed to help
them quit their cannabis use and that they through the program will have the opportunity to
communicate with a therapist. Within the next two days, they will gain access to the
internet-based treatment program, they will have access to it for two months and they will be
contacted again after three months to answer questions about their cannabis and alcohol use,
as well as about other previously mentioned issues.
The control group Individuals randomized to the control group will undergo exactly the same
procedure as the intervention group. The difference is that the control group will be
informed that they in about three months will gain access to an internet based treatment
program designed to help them quit their cannabis use (i.e. when the data collection for
follow-up is completed).
Otherwise, participants in both groups will have the opportunity to use factual information
that is available to everyone on Cannabishjalpen.se.
Follow-up procedure Study participants who were randomized to the intervention group will
have access to intervention in two months. Three months after recruitment to the study, study
participants from both groups will get an automated email invitation to participate in the
three-month follow-up. The email will include a personalized link that when clicked on will
redirect the participant to follow-up page where they will be asked to once again answer
questions about their cannabis and alcohol use, depression and anxiety, seeking professional
help for cannabis use as well as the help of family or friends and questions about whether
they have used any other internet or telephone services to reduce or quit their cannabis use.
The entire follow-up procedure will be completed via the internet.
Status | Completed |
Enrollment | 303 |
Est. completion date | December 31, 2017 |
Est. primary completion date | December 31, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Age >15 - Cannabis use 1 time/week or more often during the past six months. Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Sweden | Center for Psychiatric Research | Stockholm |
Lead Sponsor | Collaborator |
---|---|
Karolinska Institutet |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of days without cannabis use. | Past seven days | ||
Secondary | Grams of cannabis consumed. | Past three months | ||
Secondary | Reduction in frequency of cannabis use. | Past three months | ||
Secondary | Number of DSM-V criteria for cannabis dependence. | Past three months | ||
Secondary | Total score on Cannabis Abuse Screening Test (CAST). | Total score range 0-24 where higher scores indicate worse outcome. | Past three months | |
Secondary | Receiving professional help for cannabis use from relatives or friends. | Past three months | ||
Secondary | Receiving help for cannabis use from relatives or friends. | Past three months | ||
Secondary | Number of standard (alcohol) drinks. | Past seven days. | ||
Secondary | Total score on Sense of coherence Scale. | Total score range13-91, where higher scores indicate better outcome. | Past three months | |
Secondary | Total score on Montgomery Åsberg Depression Rating Scale - Self reported (MADRS-S). | Total score range 0-60 where higher scores indicate worse outcome. | Past three months | |
Secondary | Total score on Generalized Anxiety Disorder Assessment (GAD-7). | Total score range 0-21 where higher scores indicate worse outcome. | Past three months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04199468 -
THC and Ketamine Effects in Humans: Relation to Neural Oscillations and Psychosis
|
Phase 1 | |
Completed |
NCT04587700 -
Analgesic Consumption in Chronic Marijuana Users Following Orthopedic Trauma Surgery
|
||
Not yet recruiting |
NCT05899946 -
An Integrated Program to Promote Anti-cannabis Messages
|
N/A | |
Active, not recruiting |
NCT02735954 -
Colorado Marijuana Users Health Cohort
|
||
Completed |
NCT00842985 -
Dronabinol Interactions in Humans
|
N/A | |
Completed |
NCT04124432 -
Behavioral Pharmacology of Cannabis and Nicotine
|
Phase 1 | |
Active, not recruiting |
NCT04693884 -
Cannabis Inhalation: Effects on Cardiovascular Function During Rest and Exercise
|
Early Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Active, not recruiting |
NCT03560934 -
Tetrahydrocannabinol (THC) and Sleep
|
Early Phase 1 | |
Recruiting |
NCT04704271 -
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
|
Phase 1 | |
Withdrawn |
NCT03245658 -
The Effect of Cannabis in Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT04911127 -
Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
|
Phase 1 | |
Not yet recruiting |
NCT05999383 -
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
|
Phase 2 | |
Recruiting |
NCT04429568 -
THC Crossover Study
|
N/A | |
Completed |
NCT05554146 -
Pain Inflammation and Cannabis in HIV
|
N/A | |
Not yet recruiting |
NCT05320367 -
A Study of Inhaled Cannabidiol in Healthy Occasional Cannabis Users
|
Phase 1/Phase 2 | |
Completed |
NCT02567344 -
Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving
|
N/A | |
Terminated |
NCT03251326 -
Nabilone in Cannabis Users With PTSD
|
Phase 1/Phase 2 | |
Completed |
NCT00176085 -
Pharmacokinetics of THCCOOH and Its Acyl-glucuronide After Intravenous Administration of THCCOOH
|
Phase 1 |